Flunixin meglumine given in small doses: pharmacokinetics and prostaglandin inhibition in healthy horses.

The researchers investigated the effects and behaviour of different doses of flunixin meglumine, a non-steroidal anti-inflammatory drug (NSAID), in horses in terms of how long it remains in the body and its impact on prostaglandin, a group of lipids that play a key role in the body’s inflammatory responses.

Research Methodology

• The study used healthy horses as test subjects and administered varying doses of flunixin meglumine.
• Researchers utilized high-performance liquid chromatography, a method used in biochemistry and analytical chemistry to identify, quantify and purify individual components of a mixture to measure plasma concentrations of flunixin.
• The quantities of serum thromboxane B2 and 6-keto prostaglandin F1 alpha, compounds involved in inflammatory responses, were determined through radioimmunoassay, a technique used to measure antigens.

Main Findings

• The pharmacokinetics, or how the drug is absorbed, distributed, metabolised, and excreted, of flunixin showed linear characteristics within the dosage range studied. This implies that the behaviour of the drug in the body is predictable and proportional to the dose administered.
• There was significant suppression of serum thromboxane production for different time frames depending on the dose of flunixin given intravenous (IV) – 12 hours for 1.1 mg/kg, 4 hours for 0.25 mg/kg, and 3 hours for 0.1 mg/kg.
• When the flunixin was administered repeatedly at the dose of 0.25 mg/kg every 8 hours, the suppression of thromboxane production was sustained throughout the treatment.
• However, after ceasing the flunixin treatment, serum thromboxane production exceeded the pretreatment levels.
• The researchers found no significant changes in the production of 6-keto prostaglandin F1 alpha among the groups.

Conclusions

• The study demonstrated how the body processes flunixin meglumine in horses, showing a direct relationship between the administered dose and the drug’s behaviour in the body.
• The treatment also had a clear impact on inflammatory pathways by suppressing thromboxane generation, but this suppression in thromboxane production was not maintained once the treatment ceased.
• The lack of alteration in 6-keto prostaglandin F1 alpha production indicates that the effects of flunixin are not universal for all prostaglandins.

Implications

• The findings shed light on optimal dosing strategies for flunixin meglumine in horses and the drug’s potential consequences on the body’s inflammatory responses.
• This kind of information may be of interest to veterinarians and pharmaceutical scientists for designing better medication regimens for horse patients and possibly developing improvements to the drug.